Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chromosomes, Human, Pair 11/genetics , Chromosomes, Human, Pair 14/genetics , Multiple Myeloma/drug therapy , Translocation, Genetic , Aged , Aged, 80 and over , Bortezomib/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic/administration & dosage , Dexamethasone/administration & dosage , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multiple Myeloma/genetics , Multiple Myeloma/pathology , Prognosis , Retrospective Studies , Sulfonamides/administration & dosage , Survival RateSubject(s)
Antineoplastic Agents/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Leukemia, Plasma Cell/drug therapy , Molecular Targeted Therapy , Sulfonamides/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bortezomib/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Chromosomes, Human, Pair 11/genetics , Chromosomes, Human, Pair 14/genetics , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Dexamethasone/administration & dosage , Doxorubicin/administration & dosage , Hematopoietic Stem Cell Transplantation , Humans , Leukemia, Plasma Cell/complications , Leukemia, Plasma Cell/genetics , Leukemia, Plasma Cell/therapy , Male , Middle Aged , Neoplasm Proteins/antagonists & inhibitors , Neoplasm, Residual , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Recurrence , Sulfonamides/pharmacology , Translocation, Genetic , Vincristine/administration & dosageABSTRACT
Exportin 1 (XPO1), also known as chromosome maintenance 1 protein (CRM1), is the main transporter for hundreds of proteins like tumor suppressors, growth regulatory factors, oncoprotein mRNAs and others. Its upregulation leads to the inactivation of the tumor suppressor anti-neoplastic function in many cancers and logically is associated with poor prognosis. Selective inhibitors of nuclear export (SINE) are a new generation of XPO1 inhibitors that are being investigated as a promising targeted anti-cancer therapy. Selinexor is the first generation of SINE compounds that is being evaluated in many clinical trials involving solid tumors and hematological malignancies with its two approved indications for relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma. Here, we comprehensively review the current knowledge of selinexor and next generations of the SINE compounds in lymphoid and myeloid malignancies.